111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma
Metrics: PDF 802 views | HTML 1262 views | ?
Ying-Hsia Shih1,2, Cheng-Liang Peng2, Shin-Yu Lee1, Ping-Fang Chiang1,2, Cheng-Jung Yao1,5, Wuu-Jyh Lin2, Tsai-Yueh Luo2,4, Ming-Jium Shieh1,3
1Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taiwan
2Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan
3Department of Oncology, National Taiwan University Hospital and College of Medicine, Taiwan
4Institute of Radiological Science, Central University, Taiwan
5Division of Gastroenterology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
Ming-Jium Shieh, e-mail: email@example.com
Tsai-Yueh Luo, e-mail: firstname.lastname@example.org
Keywords: colorectal adenocarcinoma, EGF receptor, cetuximab, nano-SPECT/CT
Received: January 05, 2015 Accepted: April 30, 2015 Published: May 14, 2015
Colorectal adenocarcinoma is a common cause death cancer in the whole world. The aim of this study is to define the 111In-cetuximab as a diagnosis tracer of human colorectal adenocarcinoma. In this research, cell uptake, nano-SPECT/CT scintigraphy, autoradiography, biodistribution and immunohitochemical staining of EGF receptor were included. HCT-116 and HT-29 cell expressed a relatively high and moderate level of EGF receptor, respectively. The nano-SPECT/CT image of 111In-cetuximab showed tumor radiation uptake of subcutaneous HCT-116 xenograft tumor was higher than SW-620. Autoradiography image also showed that tumor of HCT-116 had high 111In-cetuximab uptake. Mice that bearing CT-26 in situ xenograft colorectal tumors showed similar high uptake in vivo and ex vivo through nano-SPECT/CT imaging at 72 hours. Metastatic HCT-116/Luc tumors demonstrated the highest uptake at 72 hours after the injection of 111In-cetuximab. Relatively, results of 111In-DTPA showed that metabolism through urinary system, especially in the kidney. The quantitative analysis of biodistribution showed count value of metastatic HCT-116/Luc tumors that treated with 111In-cetuximab had a significant difference (P < 0.05) compared with that treated with 111In-DTPA after injection 72 hours. Result of immunohistologic staining of EGF receptor also showed high EGF receptor expression and uptake in metastatic colorectal tumors. In summary, we suggested that 111In-cetuximab will be a potential tool for detecting EGF receptor expression in human metastatic colorectal carcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.